Literature DB >> 18407426

Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder.

Rose C Mantella1, Meryl A Butters, Janet A Amico, Sati Mazumdar, Bruce L Rollman, Amy E Begley, Charles F Reynolds, Eric J Lenze.   

Abstract

Age-associated alterations in hypothalamic-pituitary-adrenal (HPA) axis functioning may make individuals more susceptible to HPA dysregulation in the context of mood and anxiety disorders. Little to no research has been done to examine HPA axis function in generalized anxiety disorder (GAD), particularly in late-life GAD, the most prevalent anxiety disorder in the elderly. The study sample consisted of 71 GAD subjects and 40 nonanxious comparison subjects over 60 years of age. We examined the hypotheses that elderly individuals with GAD will have elevated salivary cortisol levels compared to nonanxious subjects, and that elevated cortisol levels in GAD will be associated with measures of symptom severity. We report that late-life GAD is characterized by elevated basal salivary cortisol levels, with higher peak cortisol levels and larger areas under the curve, compared to nonanxious subjects. Additionally, severity of GAD as measured by the GAD Severity Scale and the Penn State Worry Questionnaire are positively correlated with cortisol levels. These data demonstrate HPA axis dysfunction in late-life GAD and suggest the need for additional research on the influence of aging on HPA axis function in mood and anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407426      PMCID: PMC2766671          DOI: 10.1016/j.psyneuen.2008.03.002

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  59 in total

1.  Genetic factors, perceived chronic stress, and the free cortisol response to awakening.

Authors:  S Wüst; I Federenko; D H Hellhammer; C Kirschbaum
Journal:  Psychoneuroendocrinology       Date:  2000-10       Impact factor: 4.905

2.  Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change.

Authors:  Jens C Pruessner; Clemens Kirschbaum; Gunther Meinlschmid; Dirk H Hellhammer
Journal:  Psychoneuroendocrinology       Date:  2003-10       Impact factor: 4.905

3.  An open label trial of C-1073 (mifepristone) for psychotic major depression.

Authors:  Joseph K Belanoff; Anthony J Rothschild; Frederick Cassidy; Charles DeBattista; Etienne-Emile Baulieu; Clifford Schold; Alan F Schatzberg
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

4.  Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder.

Authors:  A M Rasmusson; D S Lipschitz; S Wang; S Hu; D Vojvoda; J D Bremner; S M Southwick; D S Charney
Journal:  Biol Psychiatry       Date:  2001-12-15       Impact factor: 13.382

5.  Rapid reversal of psychotic depression using mifepristone.

Authors:  J K Belanoff; B H Flores; M Kalezhan; B Sund; A F Schatzberg
Journal:  J Clin Psychopharmacol       Date:  2001-10       Impact factor: 3.153

6.  Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis.

Authors:  Cornelius G Bachmann; Astrid C E Linthorst; Florian Holsboer; Johannes M H M Reul
Journal:  Neuropsychopharmacology       Date:  2003-04-02       Impact factor: 7.853

7.  Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.

Authors:  A W Zobel; T Nickel; H E Künzel; N Ackl; A Sonntag; M Ising; F Holsboer
Journal:  J Psychiatr Res       Date:  2000 May-Jun       Impact factor: 4.791

8.  Awakening cortisol responses are influenced by health status and awakening time but not by menstrual cycle phase.

Authors:  B M Kudielka; C Kirschbaum
Journal:  Psychoneuroendocrinology       Date:  2003-01       Impact factor: 4.905

9.  Self-reported depressive symptoms and stress levels in healthy young men: associations with the cortisol response to awakening.

Authors:  Marita Pruessner; Dirk H Hellhammer; Jens C Pruessner; Sonia J Lupien
Journal:  Psychosom Med       Date:  2003 Jan-Feb       Impact factor: 4.312

10.  Associations between HPA axis functioning and level of anxiety in children and adolescents with an anxiety disorder.

Authors:  V L Kallen; J H M Tulen; E M W J Utens; P D A Treffers; F H De Jong; R F Ferdinand
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

View more
  50 in total

Review 1.  Advances in psychotherapy for generalized anxiety disorder.

Authors:  Eric J Garfinkle; Evelyn Behar
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study.

Authors:  Julie Loebach Wetherell; Jill A Stoddard; Kamila S White; Sander Kornblith; Hoang Nguyen; Carmen Andreescu; Sidney Zisook; Eric J Lenze
Journal:  Int J Geriatr Psychiatry       Date:  2010-09-27       Impact factor: 3.485

Review 3.  Sex differences in psychopathology: of gonads, adrenals and mental illness.

Authors:  Matia B Solomon; James P Herman
Journal:  Physiol Behav       Date:  2009-03-09

4.  An exploratory study of salivary cortisol changes during chamomile extract therapy of moderate to severe generalized anxiety disorder.

Authors:  John R Keefe; Wensheng Guo; Qing S Li; Jay D Amsterdam; Jun J Mao
Journal:  J Psychiatr Res       Date:  2017-10-16       Impact factor: 4.791

5.  Within-subject variability in repeated measures of salivary analytes in healthy adults.

Authors:  Mark V Thomas; Adam Branscum; Craig S Miller; Jeffrey Ebersole; Mohanad Al-Sabbagh; Julie L Schuster
Journal:  J Periodontol       Date:  2009-07       Impact factor: 6.993

Review 6.  Childhood stressful events, HPA axis and anxiety disorders.

Authors:  Carlo Faravelli; Carolina Lo Sauro; Lucia Godini; Lorenzo Lelli; Laura Benni; Francesco Pietrini; Lisa Lazzeretti; Gabriela Alina Talamba; Giulia Fioravanti; Valdo Ricca
Journal:  World J Psychiatry       Date:  2012-02-22

7.  Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.

Authors:  Eric J Lenze; David Dixon; Rose C Mantella; Peter M Dore; Carmen Andreescu; Charles F Reynolds; John W Newcomer; Meryl A Butters
Journal:  Int J Geriatr Psychiatry       Date:  2011-06-17       Impact factor: 3.485

Review 8.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

9.  Etiologic specificity of waking Cortisol: Links with maternal history of depression and anxiety in adolescent girls.

Authors:  Brandon L Goldstein; Greg Perlman; Roman Kotov; Joan E Broderick; Keke Liu; Camilo Ruggero; Daniel N Klein
Journal:  J Affect Disord       Date:  2016-10-11       Impact factor: 4.839

10.  Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa.

Authors:  Elizabeth A Lawson; Daniel Donoho; Karen K Miller; Madhusmita Misra; Erinne Meenaghan; Janet Lydecker; Tamara Wexler; David B Herzog; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.